NOT KNOWN DETAILS ABOUT BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES

In Section A, individuals will receive different doses and schedules of oral ABBV-744 pill to discover Protected dosing regimen. Supplemental members is going to be enrolled with the recognized monotherapy dosign program. In Section B, contributors will obtain oral ruxolitinib and ABBV-744 will probably be given as "insert-on" therapy. In Section C